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Abstract
 BACKGROUND—It is uncertain whether bridging anticoagulation is necessary for patients 
with atrial fibrillation who need an interruption in warfarin treatment for an elective operation or 
other elective invasive procedure. We hypothesized that forgoing bridging anticoagulation would 
be noninferior to bridging with low-molecular-weight heparin for the prevention of perioperative 
arterial thromboembolism and would be superior to bridging with respect to major bleeding.
 METHODS—We performed a randomized, double-blind, placebo-controlled trial in which, 
after perioperative interruption of warfarin therapy, patients were randomly assigned to receive 
bridging anticoagulation therapy with low-molecular-weight heparin (100 IU of dalteparin per 
kilogram of body weight) or matching placebo administered subcutaneously twice daily, from 3 
days before the procedure until 24 hours before the procedure and then for 5 to 10 days after the 
procedure. Warfarin treatment was stopped 5 days before the procedure and was resumed within 
24 hours after the procedure. Follow-up of patients continued for 30 days after the procedure. The 
primary outcomes were arterial thromboembolism (stroke, systemic embolism, or transient 
ischemic attack) and major bleeding.
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 RESULTS—In total, 1884 patients were enrolled, with 950 assigned to receive no bridging 
therapy and 934 assigned to receive bridging therapy. The incidence of arterial thromboembolism 
was 0.4% in the no-bridging group and 0.3% in the bridging group (risk difference, 0.1 percentage 
points; 95% confidence interval [CI], −0.6 to 0.8; P = 0.01 for noninferiority). The incidence of 
major bleeding was 1.3% in the no-bridging group and 3.2% in the bridging group (relative risk, 
0.41; 95% CI, 0.20 to 0.78; P = 0.005 for superiority).
 CONCLUSIONS—In patients with atrial fibrillation who had warfarin treatment interrupted 
for an elective operation or other elective invasive procedure, forgoing bridging anticoagulation 
was noninferior to perioperative bridging with low-molecular-weight heparin for the prevention of 
arterial thromboembolism and decreased the risk of major bleeding. (Funded by the National 
Heart, Lung, and Blood Institute of the National Institutes of Health; BRIDGE ClinicalTrials.gov 
number, NCT00786474.)
For patients with atrial fibrillation who are receiving warfarin and require an elective 
operation or other elective invasive procedure, the need for bridging anticoagulation during 
perioperative interruption of warfarin treatment has long been uncertain.1–3 Each year, this 
common clinical scenario affects approximately one in six warfarin-treated patients with 
atrial fibrillation.4,5 Warfarin treatment is typically stopped 5 days before an elective 
procedure to allow its anticoagulant effect to wane; it is resumed after the procedure, when 
hemostasis is secured, at which point 5 to 10 days of treatment is required to attain 
therapeutic anticoagulation.6,7 During the interruption of warfarin treatment, bridging 
anticoagulation therapy, typically with low-molecular-weight heparin, can be given to 
minimize the time that patients do not have an adequate level of anticoagulation, with the 
intent of minimizing the risk of perioperative arterial thromboembolism, such as stroke.6
Multiple observational studies have assessed the timing and dosing of perioperative bridging 
with low-molecular-weight heparin.8–15 However, the fundamental question of whether 
bridging anticoagulation is necessary during perioperative warfarin interruption has 
remained unanswered.16–18 Because of the lack of evidence, practice guidelines have 
provided weak and inconsistent recommendations regarding the need for bridging 
anticoagulation.19–21
Against this background, the Bridging Anticoagulation in Patients who Require Temporary 
Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE) 
trial was designed to address a simple question: in patients with atrial fibrillation, is heparin 
bridging needed during interruption of warfarin therapy before and after an operation or 
other invasive procedure? We hypothesized that forgoing bridging altogether would be 
noninferior to bridging with low-molecular-weight heparin for the prevention of 
perioperative arterial thromboembolism and would be superior to bridging with regard to the 
outcome of major bleeding.
 METHODS
 STUDY DESIGN AND OVERSIGHT
The BRIDGE trial was a randomized, double-blind, placebo-controlled trial. The protocol 
(available with the full text of this article at NEJM.org) was designed by the steering 
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committee (see the Supplementary Appendix, available at NEJM.org, for a full list of trial 
personnel) and approved by the institutional review board at each participating clinical 
center. The Duke Clinical Research Institute managed the study. The clinical coordinating 
center was responsible for study coordination, randomization, and distribution of the study 
drug. The data coordinating center was responsible for maintenance of the study database, 
data validation, and analyses. Eisai donated the dalteparin, and University of Iowa 
Pharmaceuticals prepared the matching placebo. Eisai had no role in the design or conduct 
of the study, the analysis of the data, or the preparation of the manuscript. The steering 
committee vouches for the completeness and accuracy of the data and analyses and for the 
fidelity of this report to the trial protocol.
 PATIENTS
Patients were eligible to participate in the trial if they were 18 years of age or older; had 
chronic (permanent or paroxysmal) atrial fibrillation or flutter, confirmed by means of 
previous electrocardiography or pacemaker interrogation (patients with atrial fibrillation 
associated with valvular disease, including mitral valve disease, were eligible); had received 
warfarin therapy for 3 months or longer, with an international normalized ratio (INR) 
therapeutic range of 2.0 to 3.0; were undergoing an elective operation or other elective 
invasive procedure that required interruption of warfarin therapy; and had at least one of the 
following CHADS2 stroke risk factors: congestive heart failure or left ventricular 
dysfunction, hypertension, age of 75 years or older, diabetes mellitus, or previous ischemic 
stroke, systemic embolism, or transient ischemic attack. Patients were not eligible if they 
had one or more of the following: a mechanical heart valve; stroke, systemic embolism, or 
transient ischemic attack within the previous 12 weeks; major bleeding within the previous 6 
weeks; creatinine clearance of less than 30 ml per minute; platelet count of less than 
100×103 per cubic millimeter; or planned cardiac, intracranial, or intraspinal surgery. A 
complete list of the trial inclusion and exclusion criteria is provided in the Supplementary 
Appendix. All participants provided written informed consent.
 PROCEDURES
Patients were randomly assigned to receive bridging anticoagulation therapy with dalteparin 
sodium (100 IU per kilogram of body weight administered subcutaneously twice daily) or to 
receive no bridging therapy (i.e., a matching subcutaneous placebo) from 3 days before the 
procedure until 24 hours before the procedure and then for 5 to 10 days after the procedure. 
Randomization was stratified according to study center either with the use of an interactive 
voice-response system with a toll-free telephone number and access codes or through the 
Internet. The study drugs were provided in identical vials.
The administration of study drug followed a standardized perioperative management 
protocol (Fig. 1). Warfarin treatment was stopped 5 days before the procedure, and 
administration of the study drug (dalteparin or matching placebo) was started 3 days before 
the procedure. The last preprocedure dose of dalteparin or placebo was given in the morning 
approximately 24 hours before the procedure.22,23 Warfarin treatment was restarted on the 
evening of or the day after the procedure, at the patient’s usual dose. Administration of 
dalteparin or placebo was resumed 12 to 24 hours after a minor (or low-bleeding-risk) 
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procedure and 48 to 72 hours after a major (or high-bleeding-risk) procedure.8,10 The 
designation of a procedure as having a low or high bleeding risk was guided by means of a 
classification scheme (see Table S1 in the Supplementary Appendix), but the final 
determination of risk was left to the investigator’s discretion. The patient continued to take 
the study drug after the procedure until the INR was 2 or higher on one occasion. Patients 
had follow-up encounters by telephone weekly, with the final encounter 30 to 37 days after 
the procedure. Perioperative management of antiplatelet therapy was left to the site 
investigator’s discretion.
 STUDY OUTCOMES
All study outcomes were assessed by 37 days after the procedure. The primary efficacy 
outcome was arterial thromboembolism, including stroke (ischemic or hemorrhagic), 
transient ischemic attack, and systemic embolism, and the primary safety outcome was 
major bleeding. The secondary efficacy outcomes were acute myocardial infarction, deep-
vein thrombosis, pulmonary embolism, and death, and the secondary safety outcome was 
minor bleeding. The definitions of the outcomes are provided in the Supplementary 
Appendix. All study outcomes were independently and blindly adjudicated.
 STATISTICAL ANALYSIS
The primary efficacy outcome was arterial thromboembolism at 30 days. The initial sample-
size estimates for arterial thromboembolism were based on the results of contemporaneous 
cohort studies, which suggested that the rate in the bridging group would be 1.0%.8–10,24,25 
We also assumed that the rate in the no-bridging group would be 1.0%. The primary analysis 
of efficacy was a noninferiority analysis with a one-sided test at the 0.025 level. The 
noninferiority margin was set at 1.0%. We determined that the hypothesis of inferiority 
would be rejected if the upper boundary of the 95% confidence interval for the difference in 
rates would be less than 1.0 percentage point. We prespecified that the 95% confidence 
interval for the difference in event rates would be calculated with the use of methods based 
on Barnard’s test,26 because this test permits the calculation of confidence intervals in 
analyses with small sample sizes. The confidence interval values were calculated with the 
use of StatXact software, version 9 (Cytel).27
The primary safety outcome was major bleeding at 30 days after the procedure. The null 
hypothesis of no difference in the incidence of major bleeding was tested with a two-sided 
test at the 0.05 level. The expected bleeding rates were 1.0% in the no-bridging arm and 
3.0% in the bridging arm. The P value was calculated with the use of Fisher’s mid-P test, as 
implemented in SAS software, version 9.3 (SAS Institute), and the 95% confidence interval 
was a likelihood-ratio confidence interval calculated with the same version of SAS.
We calculated that a sample of 1641 patients per group would give the study 80% power to 
detect the noninferiority of no bridging therapy, assuming a rate of arterial 
thromboembolism of 1.0% in each group and a noninferiority margin of 1.0%, at a one-sided 
alpha level of 0.025 for arterial thromboembolism and a two-sided alpha level of 0.05 for 
bleeding. With a 10% allowance for patients withdrawing from the study, the required 
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sample size was 1813 per group. We calculated that this sample size would also give the 
study more than 99% power to detect the expected difference in bleeding rates.
After approximately 850 patients had been enrolled, it was clear that the rate of arterial 
thromboembolism, as assessed by investigators who were unaware of the study-group 
assignments, was less than 0.5%, and we determined that a revised sample size of 2526 
would provide at least 90% power for each primary end point. After 1720 patients were 
enrolled, the rate of arterial thromboembolism was 0.46%, and the bleeding rate was 2.3% in 
the entire population. A revised sample size of 1882 was calculated on the basis of the 
estimate that this would provide nearly 90% power for the two primary end points.
 RESULTS
 PATIENTS
As shown in Figure 2, we recruited 1884 patients during the period from July 2009 through 
December 2014 at 108 sites in the United States and Canada; 950 patients were assigned to 
the placebo (no-bridging) group, and 934 patients were assigned to receive bridging 
treatment with dalteparin (bridging group). Table 1 shows the characteristics of the patients 
at baseline. The mean age of the patients was 71.7 years, and 73.4% of patients were male; 
the mean body weight was 95.8 kg. The mean CHADS2 score (CHADS2 scores range from 
1 to 6, with higher scores indicating a greater risk of stroke) was 2.3; 38.3% of patients had a 
CHADS2 score of 3 or higher. A total of 34.7% of the patients were taking aspirin, and 7.2% 
were taking another antiplatelet drug.
Of the 1884 patients enrolled in the trial, 1722 actually underwent the anticipated procedure 
(as-treated group), and 162 did not. The categories and types of operations and procedures 
that the participants underwent are shown in Table S2 in the Supplementary Appendix. The 
most common procedures were gastrointestinal (44.0%), cardiothoracic (17.2%), and 
orthopedic (9.2%). Overall, 89.4% of patients underwent a procedure that was classified as 
minor (low bleeding risk) according to the prespecified classification; however, 69.1% were 
treated as having a low bleeding risk by the site investigator.
 PERIOPERATIVE ANTICOAGULANT MANAGEMENT
The mean (±SD) number of doses of study drug administered was 5.0±1.1 before the 
procedure and 16.0±7.9 after the procedure (Table 2). The mean dose of dalteparin 
administered was 9093±2240 IU subcutaneously twice daily. Adherence to the study-drug 
protocol, defined as administration of 100% of protocol-specified doses of study drug, was 
86.5% before the procedure and 96.5% after the procedure.
 STUDY OUTCOMES
Of the 1884 patients enrolled in the trial, 71 discontinued participation and did not provide 
outcome data; therefore, data from 1813 patients were available for the analysis (Fig. 2). At 
30 days after the procedure, the incidence of arterial thromboembolism was 0.4% (four 
events among 918 patients) in the no-bridging group and 0.3% (three events among 895 
patients) in the bridging group (mean between-group difference, 0.1 percentage points; 95% 
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confidence interval [CI], −0.6 to 0.8; P = 0.01 for noninferiority; P = 0.73 for superiority) 
(Table 3). In an as-treated analysis, the rates of arterial thromboembolism were 0.3% (three 
events among 875 patients) in the no-bridging group and 0.4% (three events among 847 
patients) in the bridging group (mean between-group difference, 0.0 percentage points; 95% 
CI, −0.7 to 0.7; P = 0.006 for noninferiority). Patients in whom arterial thromboembolism 
occurred had a mean CHADS2 score of 2.6 (range, 1 to 4), and five of the seven events 
occurred after a minor procedure. The median time to an arterial thromboembolism event 
after the procedure was 19.0 days (interquartile range, 6.0 to 23.0).
Major bleeding occurred in 1.3% of the patients (12 of 918) in the no-bridging group and in 
3.2% (29 of 895) in the bridging group, which indicated that no bridging was superior to 
bridging with regard to major bleeding (relative risk, 0.41; 95% CI, 0.20 to 0.78; P = 0.005). 
None of the instances of major bleeding were fatal. Forgoing bridging was associated with a 
risk of minor bleeding that was significantly lower than the risk associated with bridging 
(12.0% vs. 20.9%, P<0.001). The median time to a major bleeding outcome after the 
procedure was 7.0 days (interquartile range, 4.0 to 18.0).
There was no significant difference between the groups in the rates of acute myocardial 
infarction, deep-vein thrombosis, pulmonary embolism, or death. Information on the causes 
of death and times to death is provided in Table S3 in the Supplementary Appendix.
 DISCUSSION
We found that in patients with atrial fibrillation who require perioperative interruption of 
warfarin treatment for an elective procedure, a strategy of discontinuing warfarin treatment 
without the use of bridging anticoagulation was noninferior to the use of bridging 
anticoagulation for the prevention of arterial thromboembolism; in addition, bridging 
conferred a risk of major bleeding that was nearly triple the risk associated with no bridging. 
There was also less minor bleeding without bridging than there was with bridging, and there 
was no significant difference between the groups with regard to myocardial infarction, 
venous thromboembolism, or death. Taken together, these findings show that there is a net 
clinical benefit in favor of a strategy of forgoing bridging, as compared with perioperative 
bridging with low-molecular-weight heparin.
The findings in our trial are consistent with those from nonrandomized comparisons of these 
strategies. A meta-analysis of observational studies involving a total of 12,278 patients with 
atrial fibrillation or mechanical heart valves who received or did not receive bridging with 
low-molecular-weight heparin showed no significant difference in the rate of arterial 
thromboembolism (odds ratio with bridging, 0.80; 95% CI, 0.42 to 1.54) but a higher rate of 
major bleeding (odds ratio, 3.60; 95% CI, 1.52 to 8.50) in association with bridging.28 In a 
substudy of the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY),29 
in which patients with atrial fibrillation were randomly assigned to receive warfarin or 
dabigatran in an open-label manner, bridging anticoagulation was associated with a rate of 
major bleeding that was higher than that associated with no bridging (6.8% vs. 1.6%, 
P<0.001) among 1424 warfarin-treated patients who had treatment interruption for an 
elective procedure, and there was no significant effect on arterial thromboembolism (0.5% 
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vs. 0.2%, P=0.32).30 The Outcomes Registry for Better Informed Treatment of Atrial 
Fibrillation study (ORBIT-AF), which involved 2200 patients with atrial fibrillation who 
required an elective procedure, also showed a higher rate of bleeding if bridging 
anticoagulation therapy was used during perioperative interruption of warfarin treatment.31
The rationale for the use of bridging anticoagulation therapy has been anchored on the 
premise that the associated higher bleeding risk was clinically acceptable because it would 
be offset by a lower risk of perioperative arterial throm-boembolism.32 The findings from 
the BRIDGE trial as well as from nonrandomized studies suggest that the perioperative risk 
of arterial thromboembolism in patients with atrial fibrillation during interruption of 
warfarin treatment may have been overstated and may not be mitigated by bridging 
anticoagulation. Indeed, the mechanisms of perioperative arterial thromboembolism may be 
more closely related to factors such as the type of procedure33 and to intraoperative 
alterations in blood pressure.34 The premise that warfarin interruption leads to rebound 
hypercoagulability and that the milieu of the procedure confers a prothrombotic state, which 
in turn leads to arterial thromboembolism, is not supported by the results of this trial.35–37
There are potential limitations of the BRIDGE trial. First, although we aimed to recruit a 
representative sample of patients with atrial fibrillation for whom bridging anticoagulation is 
normally considered, certain groups were underrepresented. Few patients had a CHADS2 
score of 5 or 6, although the mean score of 2.3 is similar to that among patients with atrial 
fibrillation who were assessed in recent trials and patient registries, in which the mean 
scores were between 2.1 and 2.8.29,38–40 Patients undergoing major surgical procedures 
associated with high rates of arterial thromboembolism and bleeding (e.g., carotid 
endarterectomy, major cancer surgery, cardiac surgery, or neurosurgery)19,33 were not 
represented in the trial, although the procedures performed were representative of the most 
common interventions patients undergo during an interruption of therapeutic 
anticoagulation, the majority of which are low-risk procedures, such as colonoscopy or 
ambulatory surgery.4,5,41 In addition, the findings should not be applied to patients with 
mechanical heart valves, who were specifically not included in the trial.
Second, the overall rate of arterial thromboembolism was lower than expected, which 
potentially affected the power of the trial to detect a benefit associated with bridging. 
Although we had expected perioperative arterial thromboembolism rates to be 
approximately 1.0%,8,9,12,24 the observed rate (0.4%) is similar to rates in recent studies 
involving patients who had perioperative interruption of warfarin treatment.4,5,31,42 In 
addition, the noninferiority margin we selected turned out to be large in relation to the actual 
observed event rate; it reflected the original estimate of the event rate as specified in the trial 
protocol.
Third, the observed rate of major bleeding in the bridging group (3.2%, with no instances of 
fatal bleeding) may be considered to be modest. However, our bridging protocol was 
designed to minimize bleeding, and the higher rates of bleeding reported in other studies of 
bridging anticoagulation probably reflect resumption of bridging therapy too soon after 
operations with a high bleeding risk10,43 or a lack of standardized bridging protocols.28,30
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Fourth, the reduction in the study sample size may raise concerns. This reduction was driven 
by the lower rate of arterial thromboembolism overall, with the proviso that power was 
maintained to address the primary study hypotheses. Although extending the trial was 
considered, this was not done because the added statistical power would have been 
negligible and because recruitment had been challenging throughout the course of the trial.
Finally, one may contend that the trial findings have diminished relevance because of the 
decreasing use of warfarin in the treatment of patients with atrial fibrillation, given the 
availability of the newer direct oral anticoagulants.6 However, warfarin remains widely used 
among patients with atrial fibrillation.44–46 Furthermore, the trial findings may also apply to 
the newer agents. In the substudy of the RE-LY trial discussed above, dabigatran-treated 
patients who had treatment interruption for an elective procedure had more major bleeding 
with bridging therapy than without bridging therapy, and there was no significant effect on 
arterial thromboembolism.30
In conclusion, in the BRIDGE trial, we found that for patients with atrial fibrillation who 
require temporary interruption of warfarin treatment for an elective operation or other 
elective invasive procedure, a strategy of forgoing bridging anticoagulation was noninferior 
to perioperative bridging with low-molecular-weight heparin for the prevention of arterial 
thromboembolism. The strategy of forgoing bridging treatment also decreased the risk of 
major bleeding.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. BRIDGE Study Design
Screening visits occurred between 30 days and 5 days before the planned procedure, and 
randomization (R) occurred 5 days before the procedure. Warfarin treatment was 
discontinued 5 days before the procedure, and administration of the study drug was initiated 
3 days before the procedure. It was recommended that the international normalized ratio 
(INR) be measured 1 day before the procedure; if the INR was greater than 1.8, oral vitamin 
K (1.0 to 2.5 mg) was recommended; if the INR was 1.5 to 1.8, oral vitamin K was optional. 
If the procedure or surgery was delayed up to 3 days, administration of the study drug was 
continued until 24 hours before the procedure. Warfarin treatment was restarted on the 
evening of or the day after the procedure, and the study drug was restarted 12 to 24 hours 
after a minor (or low-bleeding-risk) procedure and 48 to 72 hours after a major (or high-
bleeding-risk) procedure. Administration of the study drug was continued after the 
procedure until the INR was 2.0 or higher on one occasion. The final patient follow-up 
occurred 30 days after the procedure. LMWH denotes low-molecular-weight heparin.
Douketis et al. Page 12
N Engl J Med. Author manuscript; available in PMC 2016 July 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Screening, Randomization, and Follow-up.
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Table 1
Baseline Characteristics of the Patients.*
Characteristic No Bridging (N = 950) Bridging (N = 934)
Age — yr 71.8±8.74 71.6±8.88
Male sex — no. (%) 696 (73.3) 686 (73.4)
Race — no. (%)†
 White 860 (90.5) 849 (90.9)
 Nonwhite 88 (9.3) 82 (8.8)
 Unknown 2 (0.2) 3 (0.3)
Weight — kg 96.2±24.87 95.4±23.50
CHADS2 score‡
 Mean 2.3±1.03 2.4±1.07
 Distribution — no. (%)
  0 1 (0.1) 1 (0.1)
  1 216 (22.7) 212 (22.7)
  2 382 (40.2) 351 (37.6)
  3 229 (24.1) 232 (24.8)
  4 96 (10.1) 106 (11.3)
  5 23 (2.4) 27 (2.9)
  6 3 (0.3) 5 (0.5)
CHF or left ventricular dysfunction — no. (%) 289 (30.4) 310 (33.2)
Hypertension — no. (%) 833 (87.7) 806 (86.3)
Diabetes mellitus — no. (%) 390 (41.1) 382 (40.9)
Stroke — no. (%) 79 (8.3) 99 (10.6)
Transient ischemic attack — no. (%) 79 (8.3) 77 (8.2)
Mitral valve disease — no. (%) 165 (17.4) 142 (15.2)
 Stenosis 19 (2.0) 10 (1.1)
 Regurgitation 142 (14.9) 133 (14.2)
 Prolapse 13 (1.4) 5 (0.5)
Myocardial infarction — no. (%) 138 (14.5) 155 (16.6)
Renal disease — no. (%) 108 (11.4) 92 (9.9)
Solid malignant disease — no. (%) 68 (7.2) 52 (5.6)
Laboratory values
 Hemoglobin — g/dl 13.8±1.67 13.8±1.62
 Platelet count — thrombocytes/mm3 209,300±592,900 209,200±580,500
 INR 2.4±0.57 2.4±0.57
 Serum creatinine — mg/dl 1.1±0.32 1.1±0.32
 Creatinine clearance — ml/min 88.1±39.50 87.6±40.14
Medication use — no. (%)
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Characteristic No Bridging (N = 950) Bridging (N = 934)
 Aspirin 324 (34.1) 329 (35.2)
 Clopidogrel 30 (3.2) 21 (2.2)
 Nonsteroidal antiinflammatory drug 34 (3.6) 25 (2.7)
 COX-2 inhibitor 8 (0.8) 13 (1.4)
*
Plus–minus values are means ±SD. There were no significant differences between the groups (P<0.05). CHF denotes congestive heart failure, 
COX-2 cyclooxygenase type 2, and INR international normalized ratio.
†
Race was self-reported. The patients for whom data were unknown are those who chose not to provide information.
‡CHADS2 is a score used to estimate the risk of stroke in patients with atrial fibrillation. The score ranges from 1 to 6; 1 point each is assigned for 
congestive heart failure, hypertension, age of 75 years or older, and diabetes mellitus, and 2 points are assigned for stroke or transient ischemic 
attack.
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Table 2
Perioperative Anticoagulant Management.
Variable No Bridging (N = 950) Bridging (N = 934) P Value
Warfarin treatment
 Preprocedure time not taking warfarin 0.28
  No. of patients with data 872 839
  Mean — days 5.2±1.4 5.3±1.8
 Time to first postprocedure warfarin dose 0.40
  No. of patients with data 735 696
  Mean — days 1.5±1.3 1.4±1.0
Low-molecular-weight heparin or placebo
 Preprocedure dose 0.61
  No. of patients with data 796 768
  Mean no. of doses 5.0±0.7 5.0±1.4
 Patients in whom the last dose was taken on the morning of the day before the 
procedure — no./total no. (%)
778/796 (97.7) 734/768 (95.6) 0.02
 Time to first postprocedure dose
  Major surgery or procedure (high bleeding risk) 0.74
   No. of patients with data 235 223
   Mean — hr 53.3±31.6 51.3±27.9
  Minor surgery or procedure (low bleeding risk) 0.74
   No. of patients with data 526 497
   Mean — hr 21.1±2.3 21.0±2.4
 Postprocedure dose 0.47
  No. of patients with data 764 721
  Mean no. of doses 15.7±7.4 16.1±8.4
Aspirin treatment — no./total no. (%) 0.53
 Interruption ≥7 days before procedure 92/324 (28.4) 92/329 (28.0)
 Interruption <7 days before procedure 41/324 (12.7) 33/329 (10.0)
 No interruption 191/324 (59.0) 204/329 (62.0)
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Table 3
Study Outcomes.
Outcome No Bridging (N = 918) Bridging (N = 895) P Value
number of patients (percent)
Primary
Arterial thromboembolism 4 (0.4) 3 (0.3) 0.01*, 0.73†
 Stroke 2 (0.2) 3 (0.3)
 Transient ischemic attack 2 (0.2) 0
 Systemic embolism 0 0
Major bleeding 12 (1.3) 29 (3.2) 0.005†
Secondary
Death 5 (0.5) 4 (0.4) 0.88†
Myocardial infarction 7 (0.8) 14 (1.6) 0.10†
Deep-vein thrombosis 0 1 (0.1) 0.25†
Pulmonary embolism 0 1 (0.1) 0.25†
Minor bleeding 110 (12.0) 187 (20.9) <0.001†
*
P value for noninferiority.
†
P value for superiority.
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